-
-
-
-
-
-
-
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
-
-
-
-
-
-
-
Truist Securities Reiterates BioXcel Therapeutics (BTAI) at Buy Ahead of April 5th PDUFA, Analysts Expects Approval and Sees Company Well Prepared for Commercial Launch
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
-
-
-
-
-
-
-
Pre-Open Stock Movers 02/20: (IOTS) (STMP) (ETFC) Higher (TVTY) (SIX) (OSUR) Lower (more...)
15,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

